HC Wainwright Issues Pessimistic Estimate for BBIO Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Stock analysts at HC Wainwright cut their Q1 2025 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a research report issued to clients and investors on Tuesday, April 15th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($1.01) for the quarter, down from their prior estimate of ($0.83). HC Wainwright has a "Buy" rating and a $53.00 price objective on the stock. The consensus estimate for BridgeBio Pharma's current full-year earnings is ($3.67) per share. HC Wainwright also issued estimates for BridgeBio Pharma's Q2 2025 earnings at ($1.08) EPS, Q3 2025 earnings at ($1.02) EPS, Q4 2025 earnings at ($1.06) EPS, FY2025 earnings at ($4.17) EPS and Q1 2026 earnings at ($0.85) EPS.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The company had revenue of $5.88 million during the quarter, compared to analyst estimates of $4.04 million.

BBIO has been the topic of several other reports. Scotiabank increased their target price on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Friday, February 21st. Redburn Atlantic assumed coverage on BridgeBio Pharma in a report on Monday, March 31st. They set a "buy" rating and a $50.00 price objective on the stock. JPMorgan Chase & Co. upped their target price on BridgeBio Pharma from $44.00 to $50.00 and gave the stock an "overweight" rating in a research report on Monday, March 24th. Cantor Fitzgerald reiterated an "overweight" rating and set a $95.00 price target on shares of BridgeBio Pharma in a report on Friday, February 21st. Finally, Evercore ISI boosted their price objective on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an "outperform" rating in a research note on Monday, December 23rd. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, BridgeBio Pharma currently has a consensus rating of "Moderate Buy" and an average price target of $53.00.

BridgeBio Pharma Stock Up 1.4 %

Shares of BBIO traded up $0.46 during mid-day trading on Thursday, hitting $33.97. 609,361 shares of the company's stock were exchanged, compared to its average volume of 2,261,597. The stock has a market cap of $6.46 billion, a price-to-earnings ratio of -11.91 and a beta of 1.08. The firm has a fifty day moving average of $33.82 and a two-hundred day moving average of $30.20. BridgeBio Pharma has a twelve month low of $21.62 and a twelve month high of $39.47.

Institutional Trading of BridgeBio Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. grew its stake in shares of BridgeBio Pharma by 4,544.6% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,120,933 shares of the company's stock valued at $38,751,000 after purchasing an additional 1,096,799 shares during the period. GAMMA Investing LLC raised its stake in BridgeBio Pharma by 71.0% during the first quarter. GAMMA Investing LLC now owns 920 shares of the company's stock worth $32,000 after acquiring an additional 382 shares in the last quarter. Moss Adams Wealth Advisors LLC lifted its holdings in shares of BridgeBio Pharma by 113.8% during the first quarter. Moss Adams Wealth Advisors LLC now owns 16,202 shares of the company's stock valued at $560,000 after acquiring an additional 8,625 shares during the period. Rhumbline Advisers boosted its stake in shares of BridgeBio Pharma by 0.5% in the 1st quarter. Rhumbline Advisers now owns 220,128 shares of the company's stock valued at $7,610,000 after purchasing an additional 1,008 shares in the last quarter. Finally, California State Teachers Retirement System grew its holdings in shares of BridgeBio Pharma by 6.8% in the 4th quarter. California State Teachers Retirement System now owns 115,655 shares of the company's stock worth $3,174,000 after purchasing an additional 7,388 shares during the last quarter. Institutional investors own 99.85% of the company's stock.

Insider Buying and Selling at BridgeBio Pharma

In other BridgeBio Pharma news, Director Andrea Ellis sold 30,000 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $34.05, for a total value of $1,021,500.00. Following the completion of the sale, the director now owns 12,000 shares in the company, valued at approximately $408,600. This trade represents a 71.43 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Global Investors Lp Viking sold 3,065,616 shares of the business's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $34.90, for a total value of $106,989,998.40. Following the sale, the insider now owns 22,055,375 shares in the company, valued at approximately $769,732,587.50. This represents a 12.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 9,694,739 shares of company stock valued at $327,308,651 in the last ninety days. Company insiders own 24.66% of the company's stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.